Celularity Inc. faces heightened pressure as regulatory and funding concerns weigh on sentiment, with stocks have been trading down by -29.05 percent.
What Traders Need To Know
- Celularity has received a notice from Nasdaq for failing to file its Form 10-Qs for the quarters ended March 31, 2026 and June 30, 2026, putting it out of compliance with Nasdaq Listing Rule 5250(c)(1).
- Nasdaq has requested that Celularity submit a plan to regain compliance by 2026/09/04.
- Any compliance exception that Nasdaq might grant Celularity would extend only until 2026/11/16.
- Despite the non-compliance notice, Celularity’s shares remain listed and trading on Nasdaq while the company works to complete the delayed filings.
Weekly Update Aug 24 – Aug 28, 2026: On Sunday, August 30, 2026 Celularity Inc. stock [NASDAQ: CELU] is trending down by -29.05%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – negative
Celularity’s fundamentals are extremely weak even by early‑stage biotech standards. Revenue of ~$26.6M with mid‑teens CAGR is overwhelmed by deeply negative profitability (EBIT margin ~‑323%, net margin ~‑346%) and gross margin only 24%, implying poor manufacturing economics. Return on assets near ‑53% and negative equity (BVPS ‑$0.69) highlight accumulated losses and balance‑sheet fragility. Liquidity is acute: current ratio 0.2, quick ratio 0.1, and operating cash flow of ‑$5.1M in Q4 2025 despite working‑capital tailwinds.
Technically, CELU just shifted from a sub‑$1 base into a high‑volatility spike. The explosive move from ~$0.86 (8/26 close) to $2.01 intraday and $1.91 close on 8/27, followed by a pullback to $1.49, confirms a sharp but fragile breakout likely driven by event‑driven speculative volume. Dominant trend is short‑term bullish but unstable. Actionable level: $1.40–1.45 is key support; aggressive traders can buy near that zone with a hard stop below $1.20, targeting a retest of $1.90–2.00.
More Breaking News
- AMZN Stock Under Pressure As Rivals Target Core Businesses
- SNDG ETF Slides As Volatility Tests Momentum Traders
- Pinterest Stock Slips As Revenue Misses Rattle Traders
- MPT Stock Slides As Traders Focus On Debt And Cash Flow
Near‑term catalysts are dominated by Nasdaq non‑compliance after missed Q1 and Q2 2026 10‑Qs, with a hard timeline to present a remediation plan and regain compliance by mid‑November 2026. This elevates delisting risk versus healthcare and biotech peers, where governance and filing timeliness are generally stronger. Given negative margins, weak liquidity, and listing risk, risk‑reward is unfavorable. I view CELU as an avoid for institutional investors; trading resistance sits near $2.00, with structural support only around $0.70–0.80.
Quick Financial Overview
Celularity Inc. (CELU) is trading under a clear cloud of regulatory uncertainty after disclosing non-compliance with Nasdaq listing rules tied to missing its 2026 Q1 and Q2 Form 10-Q filings. The weekly tape shows how jumpy sentiment has become. After trading under $1 early in the period, CELU spiked toward the $2 area before fading back to around the mid-$1 zone, signaling aggressive but unstable speculative interest.
Intraday, a 5-minute candle with a high near $2.20 and low around $1.48, closing near $1.58, highlights extreme intraday volatility and wide ranges. That kind of range tells traders liquidity is there, but control is not. CELU’s fundamentals are also heavy: trailing revenue is about $26.55M, yet margins are deeply negative, with EBIT margin above -300% and profit margins similarly weak, pointing to a company still far from breakeven.
Key ratios reinforce the stress. A current ratio around 0.2 and quick ratio near 0.1 indicate tight liquidity, while negative book value per share and a price-to-sales ratio near 1.1 show the market paying roughly one year of sales for a business with large losses. Cash flow for 2025 shows operating cash burn over $5.1M and net income around -$24.36M, even as end-of-period cash rose to about $16.37M mainly through financing activities, not core operations. For traders, that cocktail means binary-feeling swings around every new filing or Nasdaq update.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.